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Abstract  
Background: Widespread use of cloth or medical masks by the public contributed to decreased 
transmission of SARS-CoV-2 in the United States throughout the COVID-19 pandemic in 2020 and 2021. 
Vaccinations granted Emergency Use Authorization in late 2020 and early 2021 offered another measure 
for preventing morbidity and mortality from COVID-19. Combining pharmaceutical and 
nonpharmaceutical interventions was estimated to further decrease transmission. However, pressure to 
repeal mask mandates is growing as more and more people are vaccinated. Therefore, it is vital to 
understand how changing masking behaviors and increasing proportion of individuals vaccinated impact 
the transmission dynamics of SARS-CoV-2.  
Methods: I evaluated how changes in masking and vaccinated proportions over time impacted cases, 
hospitalizations, and deaths. Outcomes were measured under different constant masking levels for the 
duration of the epidemic. Outcomes were also measured as masking rate decreased continuously in the 
vaccinated and unvaccinated subpopulations as vaccinated proportion increased in the full population. 
These scenarios were both tested in the presence of variants of concern with a 50% higher R0 value.  
Results: Higher masking proportions were consistent with lower cases, hospitalizations, and deaths. 
Decreasing masking continuously over time led to significantly higher cases than maintaining high 
masking throughout. This was seen more strongly when making decreased in the unvaccinated 
subpopulation, as compared to the vaccinated subpopulation. Presence of variants of concern 
exacerbated these trends, leading to high cases, hospitalizations, and deaths when masking was relaxed.    
Conclusion: Reducing masking in any group leads to an increase in cases, hospitalizations, and deaths, 
particularly in the presence of highly transmissible variants.    
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Background 
Emergence and spread of the SARS-CoV-2 virus has caused significant disruptions in the United 
States (US). First detected in the United States in mid-January, SARS-CoV-2 has continued to cause 
widespread outbreaks, harming public health and quality of life. While non-pharmaceutical 
interventions have been implemented to prevent community transmission, the recent introduction of 
COVID-19 vaccinations offers a new strategy for infection control.  This paper aims to evaluate the 
effects of population-wide masking and vaccination on SARS-CoV-2 transmission dynamics as behaviors 
change. 
SARS-CoV-2 
COVID-19 is a multi-system disease caused by the SARS-CoV-2 virus with a wide range of 
severities, causing no symptoms in about 30% of cases and causing severe or critical disease in  19%[1, 
2].  SARS-CoV-2 is primarily transmitted via respiratory droplets and aerosols though fomite 
transmission has been observed as well [3]. Furthermore, presymptomatic and asymptomatic 
transmission are known to occur, and play a significant role in the force of infection[4].  
The wide range of disease severity, presence of presymptomatic and asymptomatic 
transmission, and transmission routes have led to large outbreaks across the country, adding burden to 
the healthcare system. Hospital and intensive care unit capacity significantly decreased due to the 
number of COVID-19 patients requiring higher levels of care, leading to increases in all-cause morbidity 
and mortality. There was a 16 percent increase in mortality in the United States in 2020. COVID-19 
accounted for 11% of all US deaths in 2020. Mortality burden was highest in racial and ethnic 
minorities[5].  As of April 24th, 2021, there have been 568,237 deaths from COVID-19 reported in the 
United States. Surges in COVID-19 cases also negatively impacted economic stability, mental health, and 
education[6-8].  
Given the significant medical and nonmedical harms caused by high prevalence of COVID-19, 
transmission prevention is vital. Pharmaceutical and nonpharmaceutical interventions have been 
implemented to decrease community transmission. Uptake of these interventions has varied 
significantly across the United States offering an opportunity to evaluate advocacy of different 
interventions.  However, efforts to slow transmission have been hampered by the emergence of several 
SARS-CoV-2 variants. Of most note, the B.1.1.7 variant is known to cause an increase in transmissibility 
by roughly 50%, though no impact on vaccination efficacy has been observed to date[9, 10]. While other 
variants of concern impact transmissibility and vaccine efficacy, they collectively account for around 10% 
all lineages sequenced in the US[11]. Undoubtedly, the increasing proportion of the B.1.1.7 lineage in 
the total population has increased the need for effective infection prevention measures at a population 
level.   
Masks  
Because SARS-Co-V-2 is transmitted through respiratory droplets, occupying enclosed and 
shared spaces increases transmission risk. Masking has been shown to be a highly effective method for 
preventing transmission of SARS-CoV-2 in such settings[12, 13]. A cohort study conducted in Beijing, 
China found that masks were 79% effective in preventing household transmission of COVID-19 when 
masking was implemented prior to the primary case becoming infectious[14].  Multiple case studies 
have found similar results: mask use by the infected and/or susceptible parties significantly reduced the 
infection risk of the susceptibles. Furthermore, COVID-19 outbreaks on ships have been frequently 
observed throughout the pandemic due to the contact patterns of those on board. A retrospective study 
of the sailors on the USS Theodore Roosevelt post-outbreak demonstrated a reduction in COVID-19 risk 
in sailors who reported regular mask use during the outbreak[15]. Overall, meta analyses estimate that 
masking can reduce SARS-CoV-2 transmission by more than 30%[16].  
Whereas many countries have mandated mask use in public spaces, mask mandates in the 
United States been instituted variably at the to the state and local level. Thirty nine states in total have 
mandated mask use at any time between April 2020 and April 2021[17].  In areas without a state-wide 
mask mandate, county- or city-wide mandates have been implemented [18, 19]. The policy differences 
across the United States have provided an opportunity to evaluate efficacy of mask mandates. Studies 
from the summer of 2020 showed that states with mask mandates in place saw a decrease of 0.5-1.8 
percentage points in the COVID-19 case growth rate and a decrease of 0.7-1.9 percentage points in the 
death growth rate[20].  A county-level study found similar results; 7-day rolling incidence in counties 
with mandates decreased approximately 0.08 cases per 100,000 per day, whereas the same measure in 
counties without mandates increased by 0.11 cases per 100,000 per day[21].  
Despite the evidence supporting mask mandates as effective tools for increasing mask use, and 
therefore transmission of SARS-CoV-2, in late 2020 and early 2021, many states began repealing mask 
mandates, regardless of COVID-19 case trends[17, 22, 23].  Furthermore, enforcement of mask 
mandates has varied between states and municipalities, leading to further variation in masking 
behaviors[24]. Between July 2020 and April 2021, 65-75% of the American population are reported to be 
masking in public[25].        
As the proportion of vaccinated individuals increases, it is likely that motivation to mask will 
decrease, putting further pressure on policymakers to relax mandates. However, given the post-
mandate data, relaxing mandates too soon may lead to an increase in transmission. Therefore, 
understanding the joint impact of masking and vaccination is vital. 
Vaccination  
Vaccination research and development have been high priority since the start of the pandemic. 
On December 11th, the Pfizer/BioNTech vaccine became the first FDA-approved COVID-19 vaccination in 
the United States, and the first doses were administered 3 days later[26, 27].  
As of April 4th, 2021, there are three FDA-approved COVID-19 vaccines for use in the United 
States: BNT162b2 by Pfizer/BioNtech, mRNA-1273 by Moderna, and JNJ-78436735 by Johnson & 
Johnson/Janssen.  While the vaccination technologies and efficacies differ between the vaccines, all four 
vaccinations were highly efficacious against hospitalizations and deaths in trials (table 1). Early 
effectiveness data for the mRNA vaccines have also shown promising results. Data from a medical center 
in Israel showed that, 14 or more days after the second dose, the mRNA vaccines were 92% effective 
against documented SARS-CoV-2 infection. Data also showed the vaccines were 87% effective against 
hospitalization, and 92% effective at preventing severe disease[28]. A similar study in the United States 
showed that the Pfizer/BioNTech vaccine was 63% effective at preventing SARS-CoV-2 infections 
between 7 and 14 days after the first dose of the vaccination during an outbreak in a skilled nursing 
facility[29].   
The nominal herd immunity threshold is currently unclear. While previous estimates put the 
critical proportion to vaccinate at over 67%, emergence of the variants, proportion of recovered 
individuals, and unknown vaccine parameters complicate the estimation[30]. Regardless, eligibility and 
access impact our ability to reach this point. To date, less than 79% of the US population is old enough 
to receive a COVID-19 vaccination under the current Emergency Use Authorization[27, 31]. In the 
interim, vaccination efforts must be supported by other interventions to decrease SARS-CoV-2 
transmission.  
As the proportion of people vaccinated increases, risk behaviors – such as unmasking or 
decreased social distancing – are also likely to change, lessening the impact of nonpharmaceutical 
interventions on transmission. The current Centers for Disease Control and Prevention (CDC) guidelines 
state that individuals who are fully vaccinated can interact maskless with other fully vaccinated 
individuals or individuals from one unvaccinated household, provided there are no unvaccinated, high-
risk individuals in said household. The guidelines still recommend masking in public[32]. However, 
despite these guidelines, low vaccinated rates, and high incidence of COVID-19 cases, state and local 
governments are already feeling the public pressure to relax restrictions. 
Rationale 
Effect of social distancing, business closures, and mass vaccination on SARS-CoV-2 transmission 
has been modeled, showing the importance of continuation of these interventions through the 
vaccination campaign[33]. However, the concurrent impact of masking and vaccination on transmission 
have not been evaluated. As mask mandates are being re-evaluated by state and local governments, 
understanding the impact of masks and vaccinations on COVID-19 transmission is vital. By modifying 
masking behaviors and vaccinated proportions over time through a system of differential equations, we 
can evaluate potential intervention combinations to meet in the middle. This study aims to evaluate the 
safety of decreasing mask proportion in the US population as the proportion of fully vaccinated 





The impacts of masking and vaccination on national COVID-19 cases, deaths, and hospitalization 
were evaluated using a deterministic ordinary differential equations model (Figure 1). Compartments 
were designated for exposed, symptomatically infected, asymptomatically infected, and hospitalized 
states for both vaccinated and unvaccinated individuals. The susceptible unvaccinated state fed into the 
vaccinated state as well as the unvaccinated exposed state. Only individuals in the susceptible state 
could move into the vaccinated state. I assumed that vaccination after exposure, disease onset, or 
recovery would have no impact on transmission dynamics.  All infected and hospitalization 
compartments fed into the recovery state. Deaths were assumed to occur only from the hospitalization 
states. The simulation was run for 300 days.  
At the start of the model, individuals occupied all unvaccinated compartments, including 
recovery and death. The initial population characteristics were determined based on COVID-19 case 
data from January 2021 in the United States[34].  There initially were no fully vaccinated individuals, and 
only fully-vaccinated individuals were considered in the model.  
Individuals in the “Exposed” compartment were assumed to be infectious, though asymptomatic 
and presymptomatic infections were assumed to be less infectious than symptomatic infections[35]. 
Vaccination status was assumed to have no additional effect on infectivity of symptomatic, 
asymptomatic, or presymptomatic infections. Force of infection in the vaccinated population was 
assumed to be 90%for all documented SARS-CoV-2 infections, symptomatic and asymptomatic[36].  
Asymptomatic proportion in vaccine breakthrough cases was not known at the time of writing and was 
therefore assumed to be the same as in unvaccinated populations: 30%[16]. Hospitalization rate, 
mortality rate, and recovery rates from the symptomatically infected, vaccinated states were modified 
based on effectiveness data[28]. Vaccination rate was modeled as a proportion of the population that 
changed over time. Slope and intercept of the early vaccinations rate was calculated using a linear 
regression model run on vaccine allocation data from January through March 2021. After day 75, the 
rate was assumed to remain constant at 1.2 million fully vaccinated individuals per day. Vaccination rate 
was dropped to 0 at day 206, as it was assumed that only 70% of the population could become 
vaccinated [31]. Baseline masking percentage was set at 75% based on masking compliance data 
compiled by the Institute for Health Metrics and Evaluation. 
Incidence, hospitalizations, and deaths over time due to COVID-19 were evaluated for each of 
the simulated epidemics. The model was built and evaluated with the deSolve software in R.  All code is 
available on GitHub.  
Base scenarios 
 The model was run over 300 days to output cases, hospitalizations, and deaths over time. 
Masking proportion was varied in three testing scenarios: constant levels of masking, continuous 
decrease in masking by vaccinated proportion, and sudden decrease in masking at various vaccinated 
proportions. Total population data was plotted for the three outcomes of interest. Cases, 
hospitalizations, and deaths were also evaluated in the unvaccinated and vaccinated subpopulations; 
individuals moving through the vaccinated infectious states were considered within the vaccinated 
subpopulation, whereas individuals moving through the unvaccinated infectious states were categorized 
within the unvaccinated subpopulation.  
Testing Conditions 
Constant levels of masking were evaluated, assuming an increase in vaccinated proportion over 
the course of the epidemic, as described above. The model was simulated under five levels of mask 
coverage: 0%, 25%, 50%, 75%, 100% mask compliance (figure 2). The epidemic was also evaluated under 
75% masking in the absence of vaccination[25] (figure 2).  
Masking proportion was also varied over time as a function of vaccinated proportion: as 
vaccinated proportion increased, it was assumed that masking would decrease linearly in both the 
vaccinated and unvaccinated subpopulations. Rate of decrease in the masking proportion was evaluated 
as different in these two populations, as making behaviors are known to be different in these 
populations (cite paper). Baseline masking proportion was set at 75% at time t=0. Masking proportion in 
each group at time t was calculated by the following equation:  
(1 − 𝑘)𝑝  
where pv represented the proportion of vaccinated individuals in the total population at time t 
and k was either 0%, 25%, 50%, 75%, or 100%. Different values of k were given for the vaccinated and 
unvaccinated subpopulations in simulations to model differences in behavior between the two groups. 
Both the constant masking and continuous decrease scenarios were run assuming a higher R0 
value of 3.75. The value of β was modified accordingly for the vaccinated and unvaccinated states.  
 
Results  
Constant Masking Conditions 
 Outcomes were evaluated at the following masking proportions: 0%, 25%, 50%, 75%, and 100%. 
75% masking in the absence of vaccinations was also evaluated in a modified model.  
High masking proportion corresponded to a reduction in total and peak cases. 100% masking 
resulted in an 84% decrease in total cases as compared to the 0% masking scenario.  Presence of the 
vaccine within the population also had a substantial effect; when masking proportion was 75%, total 
cases were 26% lower with the vaccinated individuals in the population. The peak of the epidemics also 
decreased in number of cases as masking increased. However, peak cases were equal in the 75% and 
100% masking proportion scenarios. Hospitalization followed a similar pattern, decreasing as masking 
increased. Total hospitalization for all groups was reduced by 68% in the presence of vaccines within the 
population, assuming 75% masking in both test scenarios. The trends above continued for the death 
columns: deaths were lowest in the 100% masking group for both, where a higher effect was seen in the 
vaccinated subpopulation. Vaccination was seen to decrease deaths by 24% under 75% masking 
conditions (Supplemental Table 1).  
Masking as a Continuous Function of Vaccinated Proportion  
 Higher k in the unvaccinated subpopulation corresponded to lower cases, hospitalizations, and 
deaths across all values of k for the vaccinated subpopulation. This effect was seen more strongly when 
decreasing k in the unvaccinated subpopulation, as opposed to the vaccinated subpopulation.  
Comparing k=0 to k=1 in the unvaccinated subpopulation, there was an average of roughly 7.9 
million excess cases, 1.8 million excess hospitalizations, and 37,000 excess deaths when k=0. There was 
no difference in the total peak cases between the unvaccinated k=0 and k=1 scenarios. However, the 
average peak in hospitalizations in the k=0 group was around 6,000 hospitalizations higher, and the 
average peak deaths across all k values in the vaccinated subpopulation was roughly 37,000 deaths 
higher.  
In contrast, when comparing k=0 and k=1 in the vaccinated subpopulation, there were only an 
average of 2.9 million excess cases, 622,000 excess hospitalizations, and 12,000 excess deaths in the k=0 
scenario. Peak cases and hospitalizations and deaths are also higher in all groups as compared to the 
k=1, vaccinated scenario.   
In the Presence of B.1.1.7 
In the presence of a variant of the higher R0, the epidemic had a stronger peak overall at a later 
time point than in previous scenarios (Figure 3). As compared to the 100% constant masking group there 
were roughly 100 million excess cases, 30 million excess hospitalization, and in 660,000 excess deaths in 
the 0% constant masking group. The peaks in hospitalizations, cases, and deaths were also significantly 
higher in the 0% percent masking group than in the 100% masking group. Peak cases were the same in 
the 75% in 100% masking group. In the 75% no vaccine category, an excess of 10 million cases, 3 million 
hospitalizations, and 76,000 deaths were observed. Peak hospitalizations and peak deaths were also 
higher; however, peak cases were the same in the no vaccine and vaccine categories with 75% masking.  
Increase in K in the unvaccinated group was associated with an increase in cases, 
hospitalizations, and deaths, as seen in the previous simulation. When k=1 in the unvaccinated group, 
there was an average 2 million case increase across all k tested in the vaccinated subpopulation. 
Similarly, there was an increase in over 5 million hospitalizations on average across all k tested in the 
vaccinated subpopulation and an increase in 130,000 deaths.  
 
Discussion 
Synergistic effects of masking and vaccination contributed to a decrease in cases, 
hospitalizations, and deaths from COVID-19 in the scenarios modeled. This effect was greater when 
mask use decreased more quickly in the unvaccinated subpopulation as compared the vaccinated 
subpopulation. Decreasing mask use in the population overall as vaccinated proportion increases is not 
enough to stop the spread of the disease. Unvaccinated individuals, in particular, should continue to 
mask while transmission remains high. High mask compliance is especially important given the burden 
of the B.1.1.7 variant within the population. Policymakers should consider the presence of variants of 
concern, as well as the synergistic effects of masing and vaccination before considering lifting mask 
mandates.  
These results are consistent with previously published models. Reiner et. al. predicted that high 
case counts would persist for months, even in the case of high masking. Although this model did not 
explore the role of vaccinations in transmission reduction, high case counts were seen even with 95% 
masking acceptance in the general population[37].  
A major factor in the excess deaths seen throughout the COVID-19 pandemic has been hospital 
capacity. Due to the severity of the disease many patients require ventilators[2]. Shortages of supplies 
such as ventilators undoubtedly has contributed to overall morbidity and mortality seen throughout the 
COVID-19 pandemic[5]. This must also be considered when making decisions; if supply is exceeded by 
patient demand the death rate will undoubtedly increase.  
Limitations 
Other non-pharmaceutical interventions, such as social distancing and lockdown were not 
evaluated in this study. However, masking can be used even after such restrictions are lifted. Therefore, 
since masking has more longevity than social distancing and lockdown, evaluating it against vaccination 
separate from the other interventions makes sense.  
Masking proportion is not homogenous across the United States; some areas are likely to have 
higher mask compliance than others[38]. Therefore, although masking proportion averages to around 
75% in the US, the underlying variation may cause additional effects on overall transmission dynamics. 
However, due to the mobility of the population, high transmission is likely to have an impact on areas 
with lower transmission. If travel is unrestricted, as it is becoming, it is important to see how overall 
masking will be impactful. 
Scenarios modeling the increase in R0 from the presence of the B.1.1.7 variant assumes 
homogeneity of spread within the population and assumes no increase in proportion of cases caused by 
the B.1.1.7 variant. However, as the epidemic continues, it is likely that the B.1.1.7 variant would 




     Table 1: Vaccine Comparison  
 Manufacturer Pfizer/BioNTech Moderna Johnson & Johnson (Janssen) 
 Name BNT162b2 mRNA-1273 JNJ-78436735 
 Date Approved 12/11/2020 12/18/2020 02/27/2021 
 Doses Required 2 2 1 
 Days between Doses 21 28 NA 
 Ages Eligible 16+ 18+ 18+ 





All Efficacies  94.8% at >7 days after second dose 94.5% 66.9% at >14 days 
Moderate and Severe Disease --- --- 66.9% 
Efficacy – Severe Disease 75% at >7 days after second dose 100% 85% 
Hospitalization 100% 100% 93% at >14 days; 100% at >28 days 
Death 100% 100% 100% 
[27, 28, 39-43] 
  
Table 2: Parameters  
Parameter                                                                               Value                   Reference 
R0 2.5 [35] 
R0 – B.1.1.7 3.75 Assumed [44] 
Incubation (1/λ) 6 [35] 
Symptomatic Period (1/ρ) 10 [2] 
Presymptomatic Infectivity 0.5 [35] 
Asymptomatic Infectivity 0.75 [35] 
Unvaccinated - Asymptomatic Proportion 0.3 [35] 
Force of Infection 0.15625 Calculated 
Time to hospitalization (1/η) 11 [32] 
Case Fatality Rate  1.95% [45] 
Time to recovery from hospitalization (1/ϒ) 12 [4] 
Vaccine Effectiveness – All Cases  0.90 [36] 
Vaccine Effectiveness – Death  0.87 [28] 
Vaccine Effectiveness – Hospitalization  0.92 [28] 
Mask Efficacy 0.3 [16] 
Vaccination rate (δ) CALCULATED [36, 46] 
Max Fully Vaccinated per Day 1200000 Assumed 
Total Population 328,239,523 [47] 
S n- (E, A, I, H, R, M) NA 
E 1318223 [48] 
A 1040638 [48] 
I 2601595 [48] 
H 128947 [48, 49] 
R 19558126 [48, 49] 
V 0 NA 
EV 0 NA 
AV 0 NA 
IV 0 NA 
HV 0 NA 
RV 0 NA 
M 391607 [50] 
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Figure 2: Cases, hospitalizations, and deaths over time 
 
  






























Figure 2: Cases, hospitalizations, and deaths over time under continuously decreasing and constant masking proportions.  
Figure 3: Cases, hospitalizations, and deaths over time; B.1.1.7 






























Figure 3: B.1.1.7; Cases, hospitalizations, and deaths over time under continuously decreasing and constant masking proportions.  
Supplemental Tables 
Table S.1: Constant Mask Proportion in the Full Population 
 0% 25% 50% 75% 100% 
75% No 
Vaccines 
Total Cases - Unvaccinated 103631013 76664615 50104622 29351923 17203967 39670316 
Total Cases - Vaccinated 22829198 18715778 12012653 5590741 2134308 --- 
Total Cases 126460210 95380393 62117275 34942663 19338275 --- 
Peak Cases - Unvaccinated 5723020 3624790 2367451 2367451 2367451 2367451 
Peak Cases - Vaccinated 1226362 848550 475546 214444 91399 --- 
Peak Cases - Total 6607551 4159983 2451100 2367451 2367451 --- 
Total Hospitalizations - Unvaccinated 35401373 26401226 17544417 10640162 6599798 14048392 
Total Hospitalizations - Vaccinated 948948 776649 497401 231530 88603 --- 
Total Hospitalizations 36350321 27177876 18041818 10871692 6688402 --- 
Peak Hospitalizations - Unvaccinated 3289078 2097261 1312612 998889 898317 1013365 
Peak Hospitalizations - Vaccinated 48867 33818 18953 8547 3643 --- 
Peak Hospitalizations - Total 3325558 2118655 1320049 999890 898620 --- 
Total Deaths - Unvaccinated 811684 605192 402564 245550 153717 321656 
Total Deaths - Vaccinated 923 754 481 224 86 --- 
Total Deaths 812607 605946 403045 245774 153803 --- 
Peak Deaths 1204214 997553 794652 637381 545410 713263 
 
Table S.2: k=0 in Unvaccinated Subpopulation; Variable k in Vaccinated Subpopulation  
 k=0 k=0.25 k=0.5 k=0.75 k=1 
Total Cases - Unvaccinated 25832507 24200472 22930385 21933634 21141516 
Total Cases - Vaccinated 7284137 6067460 5144906 4442725 3903928 
Total Cases 33116644 30267932 28075292 26376358 25045444 
Peak Cases - Unvaccinated 2367451 2367451 2367451 2367451 2367451 
Peak Cases - Vaccinated 233544 184191 154101 142709 135659 
Peak Cases - Total 2367451 2367451 2367451 2367451 2367451 
Total Hospitalizations - Unvaccinated 9408437 8889632 8482867 8161277 7903950 
Total Hospitalizations - Vaccinated 296121 248026 211302 183151 161403 
Total Hospitalizations 9704558 9137658 8694169 8344428 8065352 
Peak Hospitalizations - Unvaccinated 900278 900273 900267 900262 900257 
Peak Hospitalizations - Vaccinated 9309 7330 6141 5687 5407 
Peak Hospitalizations - Total 18619 14661 12281 11374 10813 
Total Deaths - Unvaccinated 214436 203821 195361 188565 183043 
Total Deaths - Vaccinated 280 236 202 176 156 
Total Deaths 214716 204057 195563 188741 183199 
Peak Deaths 606323 595664 587170 580348 574806 
Table S.3: k=0.25 in Unvaccinated Subpopulation; Variable k in Vaccinated Subpopulation  
 k=0 k=0.25 k=0.5 k=0.75 k=1 
Total Cases - Unvaccinated 23616838 22331475 21333331 20548501 19921588 
Total Cases - Vaccinated 5928455 4983902 4271808 3730846 3315224 
Total Cases 29545293 27315377 25605138 24279347 23236812 
Peak Cases - Unvaccinated 2367451 2367451 2367451 2367451 2367451 
Peak Cases - Vaccinated 178604 143000 130211 124492 120233 
Peak Cases - Total 2367451 2367451 2367451 2367451 2367451 
Total Hospitalizations - Unvaccinated 8689179 8279552 7958923 7704915 7500648 
Total Hospitalizations - Vaccinated 241650 204235 175814 154065 137240 
Total Hospitalizations 8930829 8483787 8134737 7858980 7637888 
Peak Hospitalizations - Unvaccinated 899793 899787 899782 899777 899771 
Peak Hospitalizations - Vaccinated 7115 5693 5189 4962 4792 
Peak Hospitalizations - Total 14231 11385 10379 9924 9584 
Total Deaths - Unvaccinated 198979 190548 183835 178428 174015 
Total Deaths - Vaccinated 229 195 169 149 133 
Total Deaths 199208 190743 184003 178577 174148 
Peak Deaths 590815 582350 575610 570184 565755 
 
Table S.4: k=0.5 in Unvaccinated Subpopulation; Variable k in Vaccinated Subpopulation  
 k=0 k=0.25 k=0.5 k=0.75 k=1 
Total Cases - Unvaccinated 21773461 20770945 19991094 19374598 18878260 
Total Cases - Vaccinated 4840079 4116151 3571574 3157375 2837900 
Total Cases 26613540 24887096 23562668 22531974 21716160 
Peak Cases - Unvaccinated 2367451 2367451 2367451 2367451 2367451 
Peak Cases - Vaccinated 136880 119019 114582 111207 108415 
Peak Cases - Total 2367451 2367451 2367451 2367451 2367451 
Total Hospitalizations - Unvaccinated 8089498 7768979 7517611 7317419 7155208 
Total Hospitalizations - Vaccinated 197845 169089 147287 130582 117612 
Total Hospitalizations 8287342 7938068 7664899 7448001 7272820 
Peak Hospitalizations - Unvaccinated 899307 899302 899297 899291 899286 
Peak Hospitalizations - Vaccinated 5448 4744 4567 4433 4321 
Peak Hospitalizations - Total 10896 9488 9134 8865 8642 
Total Deaths - Unvaccinated 186025 179380 174076 169783 166254 
Total Deaths - Vaccinated 188 162 142 126 114 
Total Deaths 186214 179542 174218 169909 166368 
Peak Deaths 577821 571149 565825 561516 557975 
 
Table S.5: k=0.75 in Unvaccinated Subpopulation; Variable k in Vaccinated Subpopulation  
 k=0 k=0.25 k=0.5 k=0.75 k=1 
Total Cases - Unvaccinated 20244666 19467374 18859437 18374952 17980930 
Total Cases - Vaccinated 3975115 3425459 3011569 2695523 2450243 
Total Cases 24219781 22892833 21871006 21070475 20431174 
Peak Cases - Unvaccinated 2367451 2367451 2367451 2367451 2367451 
Peak Cases - Vaccinated 109218 105885 103243 101005 99047 
Peak Cases - Total 2367451 2367451 2367451 2367451 2367451 
Total Hospitalizations - Unvaccinated 7590827 7341388 7144710 6986852 6857702 
Total Hospitalizations - Vaccinated 162948 141043 124417 111629 101641 
Total Hospitalizations 7753775 7482431 7269127 7098481 6959344 
Peak Hospitalizations - Unvaccinated 898823 898817 898812 898807 898801 
Peak Hospitalizations - Vaccinated 4354 4221 4115 4026 3948 
Peak Hospitalizations - Total 8707 8442 8231 8052 7895 
Total Deaths - Unvaccinated 175187 169973 165788 162377 159548 
Total Deaths - Vaccinated 156 135 120 108 99 
Total Deaths 175343 170108 165908 162485 159647 
Peak Deaths 566950 561715 557515 554092 551254 
 
Table S.6: k=1 in Unvaccinated Subpopulation; Variable k in Vaccinated Subpopulation  
 k=0 k=0.25 k=0.5 k=0.75 k=1 
Total Cases - Unvaccinated 18975671 18374405 17900194 17518270 17203967 
Total Cases - Vaccinated 3291922 2877191 2563686 2322789 2134308 
Total Cases 22267592 21251596 20463879 19841059 19338275 
Peak Cases - Unvaccinated 2367451 2367451 2367451 2367451 2367451 
Peak Cases - Vaccinated 98303 96235 94441 92844 91399 
Peak Cases - Total 2367451 2367451 2367451 2367451 2367451 
Total Hospitalizations - Unvaccinated 7175680 6981951 6827956 6703103 6599798 
Total Hospitalizations - Vaccinated 135306 118717 106079 96300 88603 
Total Hospitalizations 7310986 7100668 6934036 6799403 6688402 
Peak Hospitalizations - Unvaccinated 898338 898333 898328 898322 898317 
Peak Hospitalizations - Vaccinated 3919 3836 3764 3700 3643 
Peak Hospitalizations - Total 7837 7672 7528 7401 7285 
Total Deaths - Unvaccinated 166104 162018 158714 155995 153717 
Total Deaths - Vaccinated 130 114 103 93 86 
Total Deaths 166234 162132 158816 156088 153803 
Peak Deaths 557841 553739 550423 547695 545410 
Table S.7: Constant Mask Proportion in the Full Population; B.1.1.7 
 0% 25% 50% 75% 100% 
75% No 
Vaccines 
Total Cases - Unvaccinated 218564440 201512972 180189066 153493259 120424674 183733284 
Total Cases - Vaccinated 19767517 21550534 23286056 24522133 24126879 --- 
Total Cases 238331958 223063505 203475122 178015391 144551552 --- 
Peak Cases - Unvaccinated 26002724 21307137 16515050 11788397 7423151 13722625 
Peak Cases - Vaccinated 2162473 2113540 2008700 1805665 1444948 --- 
Peak Cases - Total 27864212 23087436 18166265 13219643 8509424 --- 
Total Hospitalizations - Unvaccinated 73722008 68038167 60930096 52030839 41004074 62109943 
Total Hospitalizations - Vaccinated 822516 896705 968909 1020274 1003431 --- 
Total Hospitalizations 74544524 68934872 61899005 53051114 42007505 --- 
Peak Hospitalizations - Unvaccinated 13999179 11648807 9169544 6644537 4242702 7739355 
Peak Hospitalizations - Vaccinated 85586 83875 79852 71861 57561 --- 
Peak Hospitalizations - Total 14079638 11725882 9240508 6705398 4287995 --- 
Total Deaths - Unvaccinated 1688598 1558635 1396098 1192556 940125 1422930 
Total Deaths - Vaccinated 801 873 944 994 977 --- 
Total Deaths 1689400 1559509 1397042 1193550 941102 --- 
Peak Deaths 2081007 1951116 1788649 1585157 1332709 1814537 
 
Table S.8: B.1.1.7 - k=0 in Unvaccinated Subpopulation; Variable k in Vaccinated Subpopulation  
 k=0 k=0.25 k=0.5 k=0.75 k=1 
Total Cases - Unvaccinated 145121691 143267160 141435440 139630215 137854493 
Total Cases - Vaccinated 31559302 30707881 29874415 29061323 28270602 
Total Cases 176680992 173975042 171309855 168691538 166125095 
Peak Cases - Unvaccinated 8980845 8922997 8867122 8811917 8757362 
Peak Cases - Vaccinated 1907600 1878865 1850494 1822775 1795486 
Peak Cases - Total 10494116 10412358 10333064 10254865 10178364 
Total Hospitalizations - Unvaccinated 49233084 48616304 48006972 47406309 46815322 
Total Hospitalizations - Vaccinated 1312340 1277059 1242507 1208787 1175980 
Total Hospitalizations 50545424 49893363 49249479 48615096 47991302 
Peak Hospitalizations - Unvaccinated 5127623 5093714 5060948 5028507 4996561 
Peak Hospitalizations - Vaccinated 75982 74836 73701 72598 71504 
Peak Hospitalizations - Total 151964 149672 147403 145196 143008 
Total Deaths - Unvaccinated 1128032 1114028 1100185 1086530 1073086 
Total Deaths - Vaccinated 1277 1243 1209 1177 1145 
Total Deaths 1129309 1115271 1101394 1087707 1074231 
Peak Deaths 1520916 1506878 1493001 1479314 1465838 
Table S.9: B.1.1.7 - k=0.25, Unvaccinated Subpopulation; Variable, Vaccinated Subpopulation  
 k=0 k=0.25 k=0.5 k=0.75 k=1 
Total Cases - Unvaccinated 141196358 139257410 137350524 135479398 133647536 
Total Cases - Vaccinated 30835418 29922421 29034077 28173062 27341004 
Total Cases 172031776 169179831 166384600 163652460 160988540 
Peak Cases - Unvaccinated 8613373 8559111 8506054 8454312 8402824 
Peak Cases - Vaccinated 1819686 1790845 1762532 1734998 1707867 
Peak Cases - Total 10038348 9961310 9885011 9811434 9738247 
Total Hospitalizations - Unvaccinated 47923297 47278695 46644574 46022162 45412632 
Total Hospitalizations - Vaccinated 1282083 1244271 1207464 1171772 1137263 
Total Hospitalizations 49205380 48522966 47852038 47193934 46549895 
Peak Hospitalizations - Unvaccinated 4921246 4889306 4857993 4827468 4797099 
Peak Hospitalizations - Vaccinated 72488 71334 70208 69106 68024 
Peak Hospitalizations - Total 144977 142668 140417 138211 136048 
Total Deaths - Unvaccinated 1097993 1083374 1068981 1054844 1040987 
Total Deaths - Vaccinated 1247 1211 1175 1141 1107 
Total Deaths 1099240 1084585 1070157 1055984 1042094 
Peak Deaths 1490847 1476192 1461764 1447591 1433701 
 
Table S.10: B.1.1.7 - k=0.5, Unvaccinated Subpopulation; Variable, Vaccinated Subpopulation  
 k=0 k=0.25 k=0.5 k=0.75 k=1 
Total Cases - Unvaccinated 137141891 135120681 133142837 131212265 129331752 
Total Cases - Vaccinated 30033527 29058273 28115836 27208754 26338671 
Total Cases 167175418 164178954 161258673 158421018 155670423 
Peak Cases - Unvaccinated 8258243 8207474 8157905 8109595 8061610 
Peak Cases - Vaccinated 1730539 1701791 1673840 1646590 1619897 
Peak Cases - Total 9594989 9522323 9450349 9381154 9312548 
Total Hospitalizations - Unvaccinated 46570324 45898680 45241218 44599239 43973680 
Total Hospitalizations - Vaccinated 1248565 1208202 1169176 1131592 1095520 
Total Hospitalizations 47818889 47106882 46410395 45730831 45069201 
Peak Hospitalizations - Unvaccinated 4721093 4691095 4661637 4633029 4604568 
Peak Hospitalizations - Vaccinated 68941 67793 66679 65589 64524 
Peak Hospitalizations - Total 137882 135586 133359 131178 129047 
Total Deaths - Unvaccinated 1066960 1051747 1036841 1022272 1008061 
Total Deaths - Vaccinated 1215 1176 1138 1101 1066 
Total Deaths 1068175 1052922 1037978 1023373 1009128 
Peak Deaths 1459782 1444529 1429585 1414980 1400735 
 
Table S.11: B.1.1.7 - k=0.75, Unvaccinated Subpopulation; Variable, Vaccinated Subpopulation  
 k=0 k=0.25 k=0.5 k=0.75 k=1 
Total Cases - Unvaccinated 132961047 130862087 128819896 126837944 124918706 
Total Cases - Vaccinated 29149113 28112313 27118203 26169150 25266004 
Total Cases 162110160 158974400 155938100 153007094 150184710 
Peak Cases - Unvaccinated 7916856 7869478 7823885 7778851 7734856 
Peak Cases - Vaccinated 1640600 1612252 1584781 1558110 1532107 
Peak Cases - Total 9165827 9097868 9030566 8966111 8902153 
Total Hospitalizations - Unvaccinated 45175108 44477992 43799439 43140609 42502345 
Total Hospitalizations - Vaccinated 1211602 1168724 1127585 1088283 1050855 
Total Hospitalizations 46386710 45646716 44927024 44228891 43553200 
Peak Hospitalizations - Unvaccinated 4528053 4499962 4472658 4445901 4419615 
Peak Hospitalizations - Vaccinated 65362 64231 63136 62069 61028 
Peak Hospitalizations - Total 130724 128463 126272 124138 122057 
Total Deaths - Unvaccinated 1034957 1019189 1003823 988886 974398 
Total Deaths - Vaccinated 1178 1137 1097 1059 1023 
Total Deaths 1036135 1020325 1004920 989945 975421 
Peak Deaths 1427742 1411932 1396527 1381552 1367028 
 
Table S.12: B.1.1.7 - k=1, Unvaccinated Subpopulation; Variable, Vaccinated Subpopulation  
 k=0 k=0.25 k=0.5 k=0.75 k=1 
Total Cases - Unvaccinated 128658808 126489279 124392145 122370253 120424674 
Total Cases - Vaccinated 28178477 27082817 26041505 25056146 24126879 
Total Cases 156837285 153572096 150433650 147426399 144551552 
Peak Cases - Unvaccinated 7590182 7546842 7504777 7463060 7423151 
Peak Cases - Vaccinated 1550438 1522771 1495933 1470030 1444948 
Peak Cases - Total 8752997 8689787 8627993 8567900 8509424 
Total Hospitalizations - Unvaccinated 43739352 43019226 42322758 41650910 41004074 
Total Hospitalizations - Vaccinated 1171045 1125770 1082707 1041924 1003431 
Total Hospitalizations 44910397 44144996 43405465 42692834 42007505 
Peak Hospitalizations - Unvaccinated 4342776 4316679 4291599 4266636 4242702 
Peak Hospitalizations - Vaccinated 61774 60668 59599 58565 57561 
Peak Hospitalizations - Total 123549 121336 119199 117130 115123 
Total Deaths - Unvaccinated 1002025 985762 970011 954795 940125 
Total Deaths - Vaccinated 1139 1095 1053 1014 977 
Total Deaths 1003164 986857 971064 955809 941102 
Peak Deaths 1394771 1378464 1362671 1347416 1332709 
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